HEPATITIS-B virus reactivation
has occurred in patients who are
chronic carriers of the virus after
they received Bcr-Abl tyrosine
kinase inhibitors, used to treat their
chronic myeloid leukaemia, the
Therapeutic Goods Administration
has warned in its latest Medicines
Safety Update.
Other alerts relate to the use of
bone density enhancer denosumab
(Xgeva or Prolia) use associated
with QT prolongation as well as
psychiatric adverse events that
have occured in patients treated
with cystic acne treatment
isotretinoin, marketed in Australia
as Roaccutane and multiple
generics.
Visit www.tga.gov.au for details.The above article was sent to subscribers in Pharmacy Daily's issue from 12 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Aug 16
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.